Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monalizumab in AML/MDS post-Haplo-SCT
NCT06892223Phase 2Recruiting
- Sponsor
- Humanitas Research Hospital
- Start
- Dec 2021
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of monalizumab in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), myelodysplastic/myeloproliferative neoplasm (MDS/MPN), sponsored by Humanitas Research Hospital. Started Dec 2021; status: recruiting.
02
Drugs
monalizumab
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)
Beyond the preview
Go deeper on NCT06892223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06892223.